학술논문
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
Document Type
Article
Author
Source
In: eBioMedicine . (eBioMedicine, July 2023, 93)
Subject
Language
English
ISSN
23523964